Evidently in the mood for some spring cleaning, Salt Lake City’s Recursion is clearing out a chunk of its pipeline as it narrows its focus on R&D in oncology and rare diseases. The move comes roughly ...
Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program – Milestone Payment Triggered by Initiation of Additional Preclinical Studies for REV102, a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results